Ampreloxetine Funding - Schedule of Future Royalty Payment Contingencies (Details) - USD ($) $ in Thousands	5 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Development and Collaboration Agreement
Consideration allocated, less transaction costs of $0.5 million		$ 24,464
Interest accretion		974
Ending balance	$ 25,438	25,438
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Consideration allocated, less transaction costs of $0.5 million	24,464
Interest accretion	974
Ending balance	$ 25,438	25,438
Transaction costs		$ 500